Cases & Deals

Share

Baxter Ventures invests in Ocular Therapeutix

June 2013

Client(s) Baxter International Inc.

Jones Day advised Baxter Ventures in connection with its purchase of Series D-1 Convertible Preferred Stock in a private placement by Ocular Therapeutix, Inc., a developer of ophthalmic therapeutic products through use of its proprietary hydrogel technology.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.